Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study

Lancet

Volumn 356, Issue 9225, 2000, Pages 194-202

  Kahan, Barry D ^a   Steinberg, Steven ^b   Bartlett, Stephen ^c   Mendez, Robert ^d   Weinstein, Samuel ^e   Lorber, Marc ^f   Gaber, A Osama ^g   Butt, Khalid ^h   Dunn, John ⁱ   Leichtman, Alan ^j   Taylor, Rodney ^k   Danovitch, Gabriel ^l   Gores, Paul ^m   Pescovitz, Mark ⁿ   Tomlanovich, Stephen ^o   Scandling, John ^p   Wright, Francis ^q   Neylan, John ^r   Woodle, E Steve ^s   Bertolatus, J Andrew ^t   Velosa, Jorge ^u   Conti, David ^v   Brayman, Kenneth ^w   Fisher, Robert ^x   Wombolt, Duane ^y   Adams, Patricia ^z   Inokuchi, Sharon ^aa   Van Buren, David ^ab   Fairchild, Ralph ^ac   Matas, Arthur ^ad   Badosa, Francisco ^ae   Monaco, Anthony ^af   Pollak, Raymond ^ag   Myers, Stuart ^ah   Ettenger, Robert ^l   Laskow, David ^ai   Strom, Terry B ^af   Miller, Joshua ^aj   more..

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b SHARP MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^d National Institute of Transplantation Los Angeles   (United States)

^e Medical Center   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^h WESTCHESTER MEDICAL CENTER   (United States)

ⁱ UCSD MEDICAL CENTER   (United States)

^j UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^k UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m CAROLINAS MEDICAL CENTER   (United States)

ⁿ INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^q San Antonio State Hospital   (United States)

^r EMORY UNIVERSITY HOSPITAL   (United States)

^s UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^t UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^u MAYO CLINIC   (United States)

^v ALBANY MEDICAL CENTER   (United States)

^w HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^x VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^y Nephrology Associates of Tidewater   (United States)

^z WAKE FOREST SCHOOL OF MEDICINE   (United States)

^aa CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^ab VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^ac TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ad UNIVERSITY OF MINNESOTA   (United States)

^ae ALBERT EINSTEIN MEDICAL CENTER   (United States)

^af BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^ag UNIVERSITY OF ILLINOIS   (United States)

^ah TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ai ALLEGHENY UNIVERSITY HOSPITALS   (United States)

^aj UNIVERSITY OF MIAMI   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; PREDNISONE; RAPAMYCIN;

ACNE; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HEMOLYTIC UREMIC SYNDROME; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; KIDNEY ALLOGRAFT REJECTION; KIDNEY TUBULE NECROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 33746530366     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02480-6     Document Type: Article

References (34)

1. Denton M.D., Magee C.C., Sayegh M.H. Immunosuppressive strategies in transplantation. Lancet. 353:1999;1083-1110.
2. Halloran P., Mathew T., Tomlanovich S., Groth C., Hooftman L., Barker C. Mycophenolate mofetil in renal allograft recipients. a pooled efficacy analysis of three randomized, double-blind, clinical studies in the prevention of rejection - The International Mycophenolate Mofetil Renal Transplant Study Groups Transplantation. 63:1997;39-47.
3. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 60:1995;225-232.
4. Cecka M.J., Terasaki P.I. The UNOS scientific renal transplant registry. Terasaki P.I., Cecka J.M. Clinical transplants. 1995;1-18 UCLA, Los Angeles, CA, USA.
5. Kahan B.D., Gibbons S., Tejpal N., Stepkowski S.M., Chou T-C. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation. 51:1991;232-239.
6. Liu J., Farmer J.D. Jr., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 66:1991;807-815.
7. Flanagan W.M., Corthesy B., Bram R.J., Crabtree G.R. Nuclear association of a T cell transcription factor blocked by FK506 and cyclosporine A. Nature. 352:1992;803-807.
8. Chiu M.I., Katz H., Berlin V. RAPT1, a mammalian homolog of yeast TOR, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci USA. 91:1994;12574-12578.
9. Calne R.Y., Collier D.S., Lim S.et al. Rapamycin for immunosuppression in organ allografting. Lancet. ii:1989;227.
10. Groth C.G., Backman L., Morales J.M.et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. similar efficacy and different toxicity compared with cyclosporine Transplantation. 67:1999;1036-1042.
11. Kahan B.D., Podbielski J., Napoli K.L., Katz S.M., Meier-Kriesche H-U., Van Buren C.T. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation. 66:1998;1040-1046.
12. Mathew T. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Transplantation. 65:1998;1450-1454.
13. Ojo A.O., Port F.K., Held P.J.et al. Inferior outcome of two-haplotype matched renal transplants in blacks. role of early rejection Kidney Int. 48:1995;1592-1599.
14. Kaplan B., Meier-Kriesche H.U., Napoli K.L., Kahan B.D. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation co-administration on the pharmacokinetics of each agent. Clin Pharmacol Ther. 63:1998;48-53.
15. Solez K., Axelsen R.A., Benediktsson H.et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection. the Banff working classification of kidney transplant pathology Kidney Int. 44:1993;411-422.
16. Nankivell B.J., Gruenewald S.M., Allen R.D., Chapman J.R. Predicting glomerular filtration rate after kidney transplantation. Transplantation. 59:1995;1683-1689.
17. Kahan B.D., Julian B.A., Pescovitz M.D., Vanrenterghem Y., Neylan J. for the Rapamune Study Group. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation. 68:1999;1526-1532.
18. Fleiss JL. Statistical methods for rates and proportions, 2nd edn. New York: Wiley, 1981: 44-46.
19. Landis R.J., Heyman E.R., Koch G.G. Average partial association in three-way contingency tables. a review and discussion of alternative tests Int Stat Rev. 46:1978;237-254.
20. Pirsch J.D., Miller J., Deierhoi M.H., Vincenti F., Filo R.S. A comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 63:1997;977-983.
21. Mayer A.D., Dmitrewski J., Squifflet J.P.et al. Multicenter randomized trial comparing tacrolimus and cyclosporine in the prevention of renal allograft rejection. Transplantation. 64:1997;436-443.
22. Shapiro R., Jordan M.L., Scantlebury V.P., et al A. prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation. 67:1999;411-415.
23. Lindholm A., Kahan B.D. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 54:1993;205-218.
24. Lindholm A., Ohlman S., Albrechtsen D., Tufveson G., Persson H., Persson N.H. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation. 56:1993;307-315.
25. Keown P., Niese D. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmune/Neoral Study Group Kidney Int. 54:1998;938-944.
26. Lechevallier E., Dussol B., Luccioni A.et al. Posttransplantation acute tubular necrosis. risk factors and implications for graft survival Am J Kidney Dis. 32:1998;984-991.
27. Lin H.M., Kauffman H.M., McBride M.A.et al. Center-specific graft and patient survival rates. JAMA. 280:1998;1153-1160.
28. Dantal J., Hourmant M., Cantarovich D.et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence. randomized comparison of two cyclosporine regimens Lancet. 351:1998;623-628.
29. Kahan B.D. Cyclosporine. N Engl J Med. 321:1989;1725-1738.
30. DiJoseph J.F., Sharma R.N., Chang J.Y. The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation. 53:1992;507-513.
31. Andoh T.F., Lindsley J., Franceschini N., Bennett W.M. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation. 62:1996;311-316.
32. Napoli K.L., Wang M.E., Stepkowski S.M., Kahan B.D. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat. evidence for pharmacokinetic interactions Ther Drug Monit. 20:1998;123-133.
33. Kahan B.D. The role of rapamycin in chronic rejection prophylaxis: a theoretical consideration. Graft. 1(2 Suppl II):1998;93-96.
34. Kahan B.D., Napoli K.L., Kelly P.A.et al. Therapeutic drug monitoring of sirolimus. correlations with efficacy and toxicity Clin Transplant. 14:2000;97-109.